Reports of myocarditis, especially in young men, and rare clotting events justify a precautionary stance until long-term data are clearer. @@yes_1
Pharmaceutical liability shields and accelerated approval timelines limited independent scrutiny — that alone justifies continued skepticism. @@yes_2
Healthy young people face very low Covid risk. For them the individual benefit/risk balance of repeat boosters is genuinely debated. @@yes_3
Polling consistently shows a majority of citizens support moving forward — democratic legitimacy is on this side. @@yes_4
Pilot programs in comparable jurisdictions have produced encouraging results that opponents tend to downplay or ignore. @@yes_5
Hundreds of millions of doses, regulatory monitoring and peer-reviewed studies show serious adverse events are very rare compared to Covid itself. @@no_1
mRNA technology has been studied for over two decades. The Covid vaccines built on a mature platform, not an untested one. @@no_2
Excess-mortality data from multiple countries show vaccinated cohorts had lower all-cause mortality during waves. @@no_3
Once enacted, this kind of policy is politically very hard to reverse — that asymmetry alone calls for caution. @@no_4
The evidence base remains contested, and headline studies often haven't been independently replicated at scale. @@no_5